International Stem Cell (OTCMKTS:ISCO – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.03) earnings per share for the quarter, Zacks reports.
International Stem Cell Price Performance
ISCO opened at $0.18 on Friday. The stock’s 50 day moving average price is $0.16 and its 200 day moving average price is $0.15. The stock has a market cap of $1.41 million, a P/E ratio of -2.95 and a beta of 0.06. International Stem Cell has a 12 month low of $0.11 and a 12 month high of $0.27.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Articles
- Five stocks we like better than International Stem Cell
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
